Scigen logo

SIE - Scigen Share Price

A$0.068 0.0  0.0%

Last Trade - 14/08/18

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £28.8m
Position in Universe th / 1911
Unlock SIE Revenue
Relative Strength (%)
1m +2.07%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
18.2 20.8 23.6 23.5 29.1 40.4 +17.4%
-4.3 -50.3 +65.7 -14.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2017, SciGenLimited revenues increased 39% to $40.4M. Net incomedecreased 14% to $1.8M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Net income was offset by Otheroperating expenses increase of 30% to $9.5M (expense),Staff costs increase of 27% to $4.7M (expense), Interestexpense increase of 63% to $1.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


SIE Revenue Unlock SIE Revenue

Net Income

SIE Net Income Unlock SIE Revenue

Normalised EPS

SIE Normalised EPS Unlock SIE Revenue

PE Ratio Range

SIE PE Ratio Range Unlock SIE Revenue

Dividend Yield Range

SIE Dividend Yield Range Unlock SIE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SIE EPS Forecasts Unlock SIE Revenue
Profile Summary

SciGen Ltd is a biotechnology company. The Company, along with its subsidiaries, is involved in the sales, marketing and development of pharmaceutical and recombinant technology derived products. Its geographical segments include Singapore, involving in corporate office functions and sales and marketing; Australia, Korea, Thailand, Philippines, engaging in sales and marketing activities; China, engaging in regulatory activities, and Others, involving operations carried on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia and profit sharing income on sale of insulin. Its portfolio consists of biosimilar products, such as rhuman growth hormone and rhuman insulin. The Company offers a range of products, including SciTropin A, SciBenclamide, SciLodipine, SciLosar, SciLin, SciTrozole, Heri Injection, Zinc-S, Zinc-I, Gensupen, Insupen, Zonegran, Alsense and SciLocyte. In addition, the Company in-licenses and distributes pharmaceutical products and medical devices.

Last Annual December 31st, 2017
Last Interim December 31st, 2017
Incorporated November 25, 1998
No. of Shareholders: n/a
No. of Employees: 41
Sector Healthcare
Industry Pharmaceuticals
Exchange Australian Stock Exchange - SEATS
Shares in Issue 552,270,000
Free Float (0.0%)
Eligible for
SIE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SIE
Upcoming Events for SIE
Frequently Asked Questions for Scigen
What is the Scigen share price?

As of 14/08/18, shares in Scigen are trading at A$0.068, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Scigen share price performed this year?

Shares in Scigen are currently trading at A$0.068 and the price has moved by 4.62% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Scigen price has moved by -21.71% over the past year.

What are the analyst and broker recommendations for Scigen?

There are no analysts currently covering Scigen.

When will Scigen next release its financial results?

Scigen is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2018-12-31
What is the Scigen dividend yield?

Scigen does not currently pay a dividend.

Does Scigen pay a dividend?

Scigen does not currently pay a dividend.

When does Scigen next pay dividends?

Scigen does not currently pay a dividend.

How do I buy Scigen shares?

To buy shares in Scigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Scigen?

Shares in Scigen are currently trading at A$0.068, giving the company a market capitalisation of £n/a.

Where are Scigen shares listed? Where are Scigen shares listed?

Here are the trading details for Scigen:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: SIE
What kind of share is Scigen?

We were not able to load our ranking data for Scigen

Is there a Scigen share price forecast 2021?

We were not able to load any forecast data for Scigen.

How can I tell whether the Scigen share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scigen. Over the past six months, the relative strength of its shares against the market has been 0.199k%. At the current price of A$0.068, shares in Scigen are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Scigen PE Ratio?

We were not able to find PE ratio data for Scigen.

Who are the key directors of Scigen?

We were unable to find the directors for Scigen.

Who are the major shareholders of Scigen?

Here are the top five shareholders of Scigen based on the size of their shareholding:

Similar to SIE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.